-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 15th, Jingfeng Pharmaceutical issued an announcement stating that its holding subsidiary had recently received a notice from the FDA that the abbreviated new drug application for Lincomycin Hydrochloride Injection has been approved.
It is reported that lincomycin hydrochloride injection can be used for sensitive Staphylococcus, Streptococcus, Streptococcus pneumoniae and anaerobic bacteria as the cause of respiratory tract infections, skin and soft tissue infections, the female reproductive tract infections, abdominal infections and pelvic infections, two kinds of diseases can be injection mold according to the situation the hydrochloride alone or in combination with other antimicrobial agents.
Induced respiratory tract infections, skin and soft tissue infections, female genital tract infections, abdominal and pelvic infections and other infections, the latter two types of disease can be injection mold or in combination with other antibacterial agents in accordance with the case of the hydrochloride alone.
Lincomycin hydrochloride injection is used as a multi-dose sterile injection, and its development and production barriers are relatively high.
Currently in the US domestic market sales in addition to the original drug manufacturer Pfizer, generic manufacturers only XGEN PHARMACEUTICALS INC.
DJB one.
According to IMS data show that lincomycin hydrochloride injection in 2018 in the US sales market in the country was $ 16 million, due to the environmental impact of the epidemic and the large US generics, with annual sales of under 2020 to $ 2.
4 million.